News and Media
Pivit is a Natural Triple Receptor Agonist That Works by Increasing Three Hunger-Regulating Hormones: GLP-1, PYY and GIP
Available September 2025 as a Direct-to-Consumer Supplement and as a Food Ingredient
MOUNTAIN VIEW, Calif.--May 6, 2025--
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was today granted a patent for formulations of food molecules that cause significant weight loss when taken as a daily pill. The company’s Pivit supplement induces the simultaneous secretion of GLP-1, PYY and GIP, in U.S. patent US 12,290,550, Compositions for Treating Endocrine Diseases and Disorders. The company now has four granted patents that cover weight loss and blood sugar regulation.
Olfactive Biosolutions to Present May 15 at FoodTech World Cup Conference Final
Company One of Ten Finalists Globally
MOUNTAIN VIEW, Calif.--April 30, 2025--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, is a finalist in the FoodTech World Cup in Lausanne, Switzerland, and will speak to attendees there May 15. With the support of Givaudan and Nestle Research and Development Lausanne, the competition is the ultimate tournament to showcase the world’s best startups in nutrition, and spotlights the next wave of startups tackling one of the industry’s biggest challenges: Food for Health.
Co-founder and Chief Technology Officer Chris Hanson will represent Olfactive Biosolutions at the conference. Deborah Stapleton, Olfactive Biosolutions VP Media Relations, will also attend.
MOUNTAIN VIEW, Calif.--Feb. 11, 2025--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent US 12,186,299 dated Jan. 7, 2025, Compositions And Methods For Treating Hypertension By Modulating Endocrine Activity, for its breakthrough food ingredient formulation that reduces high blood pressure. Pivit™ Blood Pressure can reduce blood pressure without the side effects and drawbacks of current pharmaceutical solutions, using food molecules from the FDA-approved GRAS (Generally Recognized as Safe) list.
Olfactive Biosolutions Hires COO; Enhances Senior Management Team
MOUNTAIN VIEW, Calif.—February 4, 2025—Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, has hired David W. Allen, a long-time food industry executive, as its new Chief Operating Officer.
MOUNTAIN VIEW, Calif.—January 14, 2025—Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in U.S. patent US 12,171,727 B1 dated Dec. 24, 2024, Compositions and Methods for Treating Endocrine Diseases and Disorders.
Mountain View, Calif.—November 13, 2024—Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar reduction formulation under its U.S. patent US 12,102,664.
Olfactive Biosolutions Establishes Scientific Advisory Board
MOUNTAIN VIEW, Calif.--Oct. 29, 2024--Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has announced the formation of its Scientific Advisory Board. This board comprises esteemed experts in biotechnology, olfaction, drug discovery, and artificial intelligence, and will drive the company’s health and wellness innovations. Members have strong track records of innovation in drug discovery, synthetic biology, cellular assays, and chemical analysis.
MOUNTAIN VIEW, Calif.--Oct. 22, 2024--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a second patent for inducing the secretion of GLP-1, in U.S. patent US 12,115,134 B2 dated Oct. 15, 2024, Compositions and Methods for Treating Endocrine Diseases and Disorders.
Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Treatment of Hypertension
MOUNTAIN VIEW, Calif.--Oct. 15, 2024--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating Endocrine Activity, for its breakthrough food ingredient formulation that reduces high blood pressure. Protenx™ Blood Pressure can reduce blood pressure without the side effects and drawbacks of current pharmaceutical solutions, using food molecules from the FDA-approved GRAS (Generally Recognized As Safe) list.
Mountain View, CA. Oct. 8, 2024----Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent US 12,102,664 B2 for its breakthrough food ingredient formulation for weight loss and blood sugar reduction. Olfactive Biosolutions’ Protenx™ Weight Loss activates olfactory receptors in the gut to induce the dual secretion of natural GLP-1 and GIP to facilitate weight loss and a significant reduction in blood sugar.
Olfactive Biosolutions Wins Startup World Cup Berkeley Finals
Mountain View, CA. Sept. 16, 2024---- Olfactive Biosolutions, the leader in ectopic and chemosensory receptor technology, recently won the Berkeley Regional Finals of Startup World Cup, the premier global tech startup competition.
Establishes Company as Creator of New ‘Food Molecules as Pharmaceuticals’ Category of Healthcare
Mountain View, CA. April 2, 2024
Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss
Similar Mechanism of Action (MOA) as Semaglutide and Tirzepatide,
Proprietary Blends of Food Ingredients to Combat Obesity, Improve Health
Protenx™ Line of Food Ingredient Formulations includes dual GLP-1 / GIP receptor agonists
Mountain View, CA. Jan. 16, 2024
Olfactory and taste receptor technology to further strengthen Olfactive Biosolutions offerings for the Food & Beverage and Consumer Packaged Goods Industries
Mountain View, CA. Sept. 26, 2023
Former CEO of Patagonia Provisions Joins as Chief Sustainability Officer
Mountain View, CA. Sept. 15, 2023
Olfactive Bio Unveils Revolutionary Food-Derived Pill to Replace Ozempic
World Taste & Smell Association
https://www.tasteandsmell.world/taste-and-smell-world-news/olfactive-bio-unveils-revolutionary-food-derived-pill-to-replace-ozempic
Ectopic OR1A1 activation ameliorates hepatic lipid deposition through AMPK/SREBP-1/FASN pathway by three monoterpenes
Journal of Functional Foods
https://www.sciencedirect.com/science/article/pii/S1756464624000999
Role of ectopic olfactory receptors in glucose and lipid metabolism
Natural Science Foundation of Zhejiang Province
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15666
How smell regulates metabolism: The role of ectopically expressed olfactory receptors in lipid and glucose homeostasis
Journal of Translational Science, May 25, 2022
Human ectopic receptors and their food originated ligands: a review
Critical Reviews in Food Science and Nutrition, February 19, 2021
https://pubmed.ncbi.nlm.nih.gov/33605814/
More than meets the AI: The possibilities and limits of machine learning in olfaction
Frontiers in Neuroscience, Sept. 1, 2022
https://bit.ly/3ES93x3
New AI Strategy Mimics How Brains Learn to Smell
Quanta Magazine, Sept. 18, 2018
https://www.quantamagazine.org/new-ai-strategy-mimics-how-brains-learn-to-smell-20180918/
FoodTech World Cup @HackSummit 2025
May 15-16 | Beaulieu Congress Center, Halle 36
Avenue Bergières 10, 1004 Lausanne
https://www.hacksummit.co/foodtech-world-cup
Future Food-Tech 2025
June 2-3 | Renaissance Chicago Downtown Hotel, 1 West Upper Wacker Drive, Chicago Illinois 60601
For media inquiries please contact Deborah Stapleton, [email protected]
